SAN FRANCISCO, Nov. 11, 2025 — Leads & Copy — iRhythm Technologies, Inc. (NASDAQ: IRTC) has announced new data and findings supporting the use of its Zio® long-term continuous monitoring (LTCM) service for detecting arrhythmias. The announcements include real-world data published in Heart Rhythm, the journal of the Heart Rhythm Society, and data presented at the American Heart Association (AHA) Scientific Sessions 2025.
The study published in Heart Rhythm, titled “Relationship of Symptom Frequency and Symptom-Rhythm Correlation to Arrhythmia Type and Time to Detection: Insights from Ambulatory ECG Monitoring in Over 1 Million Patients,” featured real-world insights from over one million patients monitored with iRhythm’s Zio® LTCM service. The study showed that short-term monitoring can miss actionable arrhythmias, even in patients with frequent symptoms, and that patient-reported symptoms were infrequently associated with arrhythmia events. Data indicated nearly two-thirds (64%) of daily-symptom patients with actionable arrhythmias were undetected in the first 48 hours. It also showed the mean time to first detected arrhythmia exceeded 48 hours for all arrhythmia types, regardless of symptom frequency. The symptom–rhythm correlation (SRC) was notably low for most arrhythmias, with less than 20% of patients documenting a symptom coinciding with an arrhythmic episode.
Data presented at the American Heart Association (AHA) Scientific Sessions 2025 included an analysis evaluating iRhythm’s patient home enrollment pathway for its Zio® monitoring service. The data demonstrated that patients can successfully self-apply and activate the Zio 14-day patch-based LTCM device shipped directly to their home, achieving high compliance with the prescribed wear duration and data quality comparable to in-clinic application. The analysis of 742,268 Zio LTCM devices, showed that median wear time and percent analyzable ECG time were high and comparable across groups (>13.8 days and >98%, respectively). MyZio mobile app use was more common among home enrollment patients (52% vs. 17%) and associated with fewer early terminations, greater analyzable time, and a higher rate of compliance with return of devices for analysis within 45 days (93% vs. 80%).
Additional large-scale real-world analyses presented at AHA 2025 provided expanded insights into cardio-kidney-metabolic (CKM)/chronic kidney disease (CKD) risk and revealed earlier arrhythmia detection supporting proactive monitoring in at-risk populations. The analyses, encompassing data from more than 10 million patients, showed that arrhythmia incidence increased from 6.3% after Stage 1 to 9.2% after Stage 2 and 12.5% after Stage 3. One study revealed arrhythmias occurred before CKD diagnosis in 58 percent of patients, with AF being the most common arrhythmia (75–83 percent).
“These findings challenge the long-held clinical assumptions and payor guidelines that frequent symptoms justify short-duration monitoring,” said Mintu Turakhia, MD, Chief Medical and Scientific Officer and EVP of Advanced Technologies at iRhythm.
Kassandra Perry, Media Contact, mediarelations@irhythmtech.com;
Stephanie Zhadkevich, Investor Contact, investors@irhythmtech.com
Source: iRhythm Technologies, Inc.
